Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Tonix Pharm Hldg (TNXP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 10,899
  • Shares Outstanding, K 6,089
  • Annual Sales, $ 0 K
  • Annual Income, $ -26,090 K
  • 60-Month Beta 1.90
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.54

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.99
  • Number of Estimates 3
  • High Estimate -0.94
  • Low Estimate -1.04
  • Prior Year -7.30
  • Growth Rate Est. (year over year) +86.44%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.50 +5.33%
on 06/19/19
2.49 -36.55%
on 05/23/19
-0.06 (-3.66%)
since 05/17/19
3-Month
1.50 +5.33%
on 06/19/19
3.14 -49.68%
on 04/04/19
-1.05 (-39.92%)
since 03/19/19
52-Week
1.50 +5.33%
on 06/19/19
48.90 -96.77%
on 06/22/18
-44.42 (-96.57%)
since 06/19/18

Most Recent Stories

More News
Tonix Pharmaceuticals Will Present Results from Pharmacokinetic Analyses of TNX-102 SL in a Poster Presentation at the American Society of Clinical Psychopharmacology

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) today announced that it will be presenting pharmacokinetic analyses of TNX-102 SL* in a poster at the American Society of Clinical...

TNXP : 1.58 (-11.73%)
Tonix Pharmaceuticals Announces Director Stepping Down

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix) announced that Donald W. Landry, M.D., Ph.D., is stepping down from the Company's Board of Directors, effective May 16, 2019. Dr. Landry has served...

TNXP : 1.58 (-11.73%)
Tonix Pharmaceuticals Reports First Quarter 2019 Financial Results and Operational Highlights

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company developing pharmaceutical products to treat psychiatric and pain conditions, and biological...

TNXP : 1.58 (-11.73%)
Tonix Pharmaceuticals Announces New Board Member, Daniel Goodman, M.D., MBA

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix) today announced the appointment of Daniel Goodman, M.D., MBA to its Board of Directors, effective May 6, 2019.

TNXP : 1.58 (-11.73%)
Recent Analysis Shows Precision Drilling, Taitron Components, Image Sensing, and Tonix Pharmaceuticals Holding Market Influences -- Renewed Outlook, Key Drivers of Growth

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Precision Drilling Corporation...

TNXP : 1.58 (-11.73%)
ISNS : 4.89 (+1.24%)
PDS : 1.72 (+1.18%)
TAIT : 3.18 (+4.95%)
Tonix Pharmaceuticals Announces that Breakthrough Therapy Designation Remains in Effect for Tonmya(R) for the Treatment of Posttraumatic Stress Disorder

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company developing pharmaceutical products to treat psychiatric and pain conditions, and biological...

TNXP : 1.58 (-11.73%)
Tonix Pharmaceuticals Plans to Expand TNX-102 SL Phase 3 Program Beyond PTSD to Include Fibromyalgia

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company focused on developing pharmaceutical products to treat serious neuropsychiatric and...

TNXP : 1.58 (-11.73%)
Tonix Pharmaceuticals to Present at Upcoming Investor Conferences

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) announced today that Company management will present at two upcoming investor conferences.

TNXP : 1.58 (-11.73%)
Tonix Pharmaceuticals to Participate at Upcoming Investor Conferences

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) announced today that Company management will participate and host investor meetings at the following two investor conferences:

TNXP : 1.58 (-11.73%)
Tonix Pharmaceuticals Enrolls First Participant in the "RECOVERY" Study -- a New Phase 3 Trial of Tonmya(R) for the Treatment of Posttraumatic Stress Disorder

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) a clinical-stage biopharmaceutical company focused on developing pharmaceutical products to treat serious neuropsychiatric conditions...

TNXP : 1.58 (-11.73%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Soft. Long term indicators fully support a continuation of the trend.

See More Share

Trade TNXP with:

Business Summary

Tonix Pharmaceuticals Holding Corp. is a specialty pharmaceutical company focused on developing new pharmaceutical products for CNS conditions. The Company develops therapies for disorders that include fibromyalgia syndrome and post-traumatic stress disorder. Its lead product candidates include TNX-102,...

See More

Key Turning Points

2nd Resistance Point 1.93
1st Resistance Point 1.86
Last Price 1.58
1st Support Level 1.65
2nd Support Level 1.51

See More

52-Week High 48.90
Fibonacci 61.8% 30.79
Fibonacci 50% 25.20
Fibonacci 38.2% 19.61
Last Price 1.58
52-Week Low 1.50

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar